Hodgkin lymphoma
Hodgkin Lymphoma, formerly known as Hodgkin's disease, Hodgkin's disease, or Hodgkin's lymphoma, is a cancerous change originating from lymphocytes. The name "Hodgkin" comes from Thomas Hodgkin, who first described this unique malignant disease of the lymphatic system in 1832. It often begins in a group of lymph nodes and then spreads to other lymph nodes or extranodal organs and tissues. Its histopathological feature is the appearance of malignant Reed-Sternberg cells. Currently, the application of chemotherapy, radiotherapy and bone marrow transplantation in the treatment of Hodgkin's lymphoma has made it a curable tumor.
-
Site of disease:
lymph -
Infectious :
Not contagious -
Frequent population:
The peak age is 15 to 34 years old, with more males than females -
Related symptoms:
Lymphatic fluid outflow herpes lymph node enlargement thrombocytopenia skin itching -
Concurrent disease:
Related Drugs
Epirubicin Hydrochloride for Injection
Indication: Used to treat leukemia, malignant lymphoma, multiple myeloma, breast cancer, lung cancer, soft tissue sarcoma, gastric cancer, colorectal cancer, ovarian cancer, etc.
Manufacturer:
Pfizer Pharmaceutical Wuxi Co., Ltd.
Epirubicin Hydrochloride for Injection
Indication: Treatment of malignant lymphoma, breast cancer, soft tissue sarcoma, esophageal cancer, gastric cancer, liver cancer, pancreatic cancer, melanoma, colorectal cancer, ovarian cancer, multiple myeloma, leukemia.
Manufacturer:
Han Hui Pharmaceuticals Company Limited
Cytarabine Injection
Indication: It is mainly used to treat acute non-lymphocytic leukemia (usually used in combination with anthracyclines such as daunorubicin), blast crisis of chronic myeloid leukemia, refractory acute lymphocytic leukemia and non-Hodgkin's lymphoma. Intrathecal injection is used to treat meningeal leukemia and meningeal metastases.
DOXORUBICIN HYDROCHLORIDE- doxorubicin hydrochloride_injection, solution
Indication: Doxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer. 1 for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma. 2 Doxorubicin Hydrochloride Injection is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer. Doxorubicin Hydrochloride Injection is indicated for the treatment of: acute lymphoblastic leukemia acute myeloblastic leukemia Hodgkin lymphoma non-Hodgkin lymphoma (NHL) metastatic breast cancer metastatic Wilms' tumor metastatic neuroblastoma metastatic soft tissue sarcoma metastatic bone sarcoma metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma.
Manufacturer:
Athenex Pharmaceutical Division, LLC.
Related Ingredients
-
Epirubicin list
56420-45-2 -
Epirubicin hydrochloride list
56390-09-1 -
Cytarabine list
147-94-4